The future of cancer immunotherapy: microenvironment-targeting combinations is a research paper published in Cell Research (2020). On theSindex it has a DataRank of 8.5. It has been cited 782 times, with 200 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.999
From this paper's citation signal
Citation Network Contribution
7.5
From 200 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 200 citers.
NCI NIH HHS
Grant: P30 CA008748
NCATS NIH HHS
Grant: UL1 TR002384
NCATS NIH HHS
Grant: UL1 TR000457
National Institutes of Health
Grant: 3UL1TR000457-08S1
Clinical and Translational Science Center
National Institutes of Health
Grant: 2P30CA008748-43
MOUSE GENETICS
FWCI
37.21
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival
Additional file 1 of Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival
Additional file 2 of Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival
Additional file 2 of Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival
Additional file 1 of Identification of a cytokine-dominated immunosuppressive class in squamous cell lung carcinoma with implications for immunotherapy resistance
Additional file 1 of Identification of a cytokine-dominated immunosuppressive class in squamous cell lung carcinoma with implications for immunotherapy resistance
Additional file 1 of Expression characteristic, immune signature, and prognosis value of EFNA family identified by multi-omics integrative analysis in pan-cancer
Additional file 1 of Expression characteristic, immune signature, and prognosis value of EFNA family identified by multi-omics integrative analysis in pan-cancer
Additional file 1 of EMID2 is a novel biotherapeutic for aggressive cancers identified by in vivo screening
Additional file 1 of EMID2 is a novel biotherapeutic for aggressive cancers identified by in vivo screening
Additional file 4 of EMID2 is a novel biotherapeutic for aggressive cancers identified by in vivo screening
Additional file 4 of EMID2 is a novel biotherapeutic for aggressive cancers identified by in vivo screening
Additional file 1 of Validation of the C-X-C chemokine receptor 3 (CXCR3) as a target for PET imaging of T cell activation
Additional file 1 of Validation of the C-X-C chemokine receptor 3 (CXCR3) as a target for PET imaging of T cell activation
Additional file 16 of Blood-based molecular and cellular biomarkers of early response to neoadjuvant PD-1 blockade in patients with non-small cell lung cancer
Additional file 14 of Blood-based molecular and cellular biomarkers of early response to neoadjuvant PD-1 blockade in patients with non-small cell lung cancer
Additional file 16 of Blood-based molecular and cellular biomarkers of early response to neoadjuvant PD-1 blockade in patients with non-small cell lung cancer
Additional file 11 of Blood-based molecular and cellular biomarkers of early response to neoadjuvant PD-1 blockade in patients with non-small cell lung cancer
Additional file 15 of Blood-based molecular and cellular biomarkers of early response to neoadjuvant PD-1 blockade in patients with non-small cell lung cancer
Additional file 14 of Blood-based molecular and cellular biomarkers of early response to neoadjuvant PD-1 blockade in patients with non-small cell lung cancer